Project information | Sotagliflozin for treating type 2 diabetes [ID1657] | Guidance

Suggested remit: To appraise the clinical and cost effectiveness of sotagliflozin within its marketing authorisation for treating type 2 diabetes.

Status	Awaiting development
Decision	None selected
Process	TA
ID number	1657

Project Team

Project lead

Michelle Adhemar

Email enquiries

If you have any queries please email scopingta@nice.org.uk

Timeline

Key events during the development of the guidance:

Date	Update
26 June 2020	The National Institute for Health and Care Excellence (NICE) has been asked to consider an appraisal of sotagliflozin for treating type 2 diabetes ID1657. We have recently invited stakeholders to respond to a written consultation on the draft scope for this appraisal. Following the receipt of an update from the company that market sotagliflozin, NICE has agreed that continuing the scoping exercise at this time would not be appropriate. As a consequence of this the scoping exercise has been cancelled and will be rearranged at a later date. Please accept our apologies for any inconvenience.

Date

Update

26 June 2020

The National Institute for Health and Care Excellence (NICE) has been asked to consider an appraisal of sotagliflozin for treating type 2 diabetes ID1657. We have recently invited stakeholders to respond to a written consultation on the draft scope for this appraisal. Following the receipt of an update from the company that market sotagliflozin, NICE has agreed that continuing the scoping exercise at this time would not be appropriate. As a consequence of this the scoping exercise has been cancelled and will be rearranged at a later date. Please accept our apologies for any inconvenience.

For further information on our processes and methods, please see our CHTE processes and methods manual